Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00131911 · ClinicalTrials.gov registry record · Phase 2
Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
A Phase 2 study of Neuroendocrine Tumor and Insulinoma, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 93
- Enrollment target
- 1
- Study location
NCT00131911 is a Phase 2 study of Neuroendocrine Tumor and Insulinoma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 93 participants, below the 129-participant average among 6 other Neuroendocrine Tumor trials with a reported enrollment target (28% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00131911, a Phase 2 study of Neuroendocrine Tumor and Insulinoma, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 93 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial is studying how well sorafenib tosylate works in treating patients with progressive metastatic neuroendocrine tumors. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
Conditions Studied
Interventions
- DRUG sorafenib tosylate
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2005-06 |
| Est. Completion | 2013-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00131911
The ClinicalTrials.gov registry entry for NCT00131911 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 93 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 129-participant average among 6 other Neuroendocrine Tumor trials with a reported enrollment target (28% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Neuroendocrine Tumor appearing as the primary indexed condition, and to 1 intervention - of which sorafenib tosylate is the first listed.
NCT00131911 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT00131911 about?
NCT00131911 is a clinical study titled "Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors". This phase II trial is studying how well sorafenib tosylate works in treating patients with progressive metastatic neuroendocrine tumors. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
What is the current status of trial NCT00131911?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 93 participants. The study started on 2005-06. Estimated completion is 2013-04.
What conditions does trial NCT00131911 study?
This clinical trial studies the following conditions: Neuroendocrine Tumor, Insulinoma, Metastatic Gastrointestinal Carcinoid Tumor, Gastrinoma, Glucagonoma.
What interventions are being tested in trial NCT00131911?
The interventions under investigation include: sorafenib tosylate (DRUG).
Who is sponsoring clinical trial NCT00131911?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00131911 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroendocrine Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
COMPLETED · Phase 2
-
Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization
COMPLETED · Phase 2
-
Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT
COMPLETED · Phase 2
-
An Investigational Scan ([68Ga] Ga-FAPI-04 PET/CT) for the Imaging of Patients With High-Grade Neuroendocrine Cancer
RECRUITING · Early Phase 1
-
Breathing Practice for Brain and Mental Health in Cancer and Neurodegenerative Diseases
RECRUITING · NA
-
Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.